205 related articles for article (PubMed ID: 18025250)
1. The reliability and validity of self- and investigator ratings of ADHD in adults.
Adler LA; Faraone SV; Spencer TJ; Michelson D; Reimherr FW; Glatt SJ; Marchant BK; Biederman J
J Atten Disord; 2008 May; 11(6):711-9. PubMed ID: 18025250
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
[TBL] [Abstract][Full Text] [Related]
3. Validation of the adult ADHD investigator symptom rating scale (AISRS).
Spencer TJ; Adler LA; Meihua Qiao ; Saylor KE; Brown TE; Holdnack JA; Schuh KJ; Trzepacz PT; Kelsey DK
J Atten Disord; 2010 Jul; 14(1):57-68. PubMed ID: 19794135
[TBL] [Abstract][Full Text] [Related]
4. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.
Adler LA; Spencer TJ; Williams DW; Moore RJ; Michelson D
J Atten Disord; 2008 Nov; 12(3):248-53. PubMed ID: 18448861
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
6. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
Adler LA; Sutton VK; Moore RJ; Dietrich AP; Reimherr FW; Sangal RB; Saylor KE; Secnik K; Kelsey DK; Allen AJ
J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
9. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
[TBL] [Abstract][Full Text] [Related]
10. Emotional dysregulation in adult ADHD and response to atomoxetine.
Reimherr FW; Marchant BK; Strong RE; Hedges DW; Adler L; Spencer TJ; West SA; Soni P
Biol Psychiatry; 2005 Jul; 58(2):125-31. PubMed ID: 16038683
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
[TBL] [Abstract][Full Text] [Related]
12. Investigator ratings of ADHD symptoms during a randomized, placebo-controlled trial of atomoxetine: a comparison of parents and teachers as informants.
Bohnstedt BN; Kronenberger WG; Dunn DW; Giauque AL; Wood EA; Rembusch ME; Lafata D
J Atten Disord; 2005 May; 8(4):153-9. PubMed ID: 16110045
[TBL] [Abstract][Full Text] [Related]
13. Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo.
Buitelaar JK; Wilens TE; Zhang S; Ning Y; Feldman PD
J Child Psychol Psychiatry; 2009 Mar; 50(3):335-42. PubMed ID: 19309330
[TBL] [Abstract][Full Text] [Related]
14. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
Biederman J; Gao H; Rogers AK; Spencer TJ
Biol Psychiatry; 2006 Nov; 60(10):1106-10. PubMed ID: 16806096
[TBL] [Abstract][Full Text] [Related]
15. Factor structure of the Conners Adult ADHD Rating Scale (CAARS) for substance users.
Cleland C; Magura S; Foote J; Rosenblum A; Kosanke N
Addict Behav; 2006 Jul; 31(7):1277-82. PubMed ID: 16169157
[TBL] [Abstract][Full Text] [Related]
16. Reliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients.
Sandra Kooij JJ; Marije Boonstra A; Swinkels SH; Bekker EM; de Noord I; Buitelaar JK
J Atten Disord; 2008 Jan; 11(4):445-58. PubMed ID: 18083961
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD.
Adler L; Dietrich A; Reimherr FW; Taylor LV; Sutton VK; Bakken R; Allen AJ; Kelsey D
Ann Clin Psychiatry; 2006; 18(2):107-13. PubMed ID: 16754416
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.
Spencer TJ; Sallee FR; Gilbert DL; Dunn DW; McCracken JT; Coffey BJ; Budman CL; Ricardi RK; Leonard HL; Allen AJ; Milton DR; Feldman PD; Kelsey DK; Geller DA; Linder SL; Lewis DW; Winner PK; Kurlan RM; Mintz M
J Atten Disord; 2008 Jan; 11(4):470-81. PubMed ID: 17934184
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]